Advanced Search

 

Study ID Status Title Patient Level Data
3065A1-115 Completed Pharmacokinetics of Retigabine and its N-Acetylated Metabolite (NAMR) and the Impact on Serum Bilirubin in Subjects with Different Genotypes for UDP-glucuronyl transferase 1A1 (UGT1A1) and N-acetyl transferase (NAT2) Study Listed on ClinicalStudyDataRequest.com
3065A1-117 Completed Tolerability of intravenous dose titration of retigabine administered as short time infusion in healthy male volunteers Study Listed on ClinicalStudyDataRequest.com
3065A1-120 Completed Relative bioavailability of retigabine (D-23129) from various modified release formulations (TESTS) versus immediate release capsules (REFERENCE) in healthy male volunteers – second study
3065A1-121 Completed A study of the effects of blood collection processing on measured retigabine concentrations in healthy male volunteers
3065A1-123 Completed Absolute and Relative Bioavailability of Retigabine IR capsules in Healthy Male Subjects Study Listed on ClinicalStudyDataRequest.com
3065A1-200/201 Completed Efficacy, Tolerability, Safety and Pharmacokinetics of orally administered D-23129 in patients with partial onset seizures
3065A1-202 Completed A Multicenter, Open-Label, Safety, Tolerability, and Preliminary Efficacy Study of GKE-841 (Retigabine, D-23129) Administered as Add-On Therapy to Patients with Epilepsy Currently Receiving Monotherapy with an Established Anticonvulsive Agent
3065A1-205 Completed A Randomized, Double-blind, Placebo-controlled, Parallel group, Multicenter, Dose-ranging, Efficacy and Safety Study of Retigabine (D-23129; GKE-841) Administered as Add-on Therapy in Patients With Partial Epilepsy Study Listed on ClinicalStudyDataRequest.com
3065A1-208 Completed A multicenter, open-label, long-term, safety tolerability, and efficacy study of GKE-841 (retigabine D-23129) in adult patients with epilepsy (extension of study 202) Study Listed on ClinicalStudyDataRequest.com
3065A1-209 Completed An Open-Label, Sequential-Group Feasibility Study to Assess the Tolerability of Rapid Dose Escalation of Retigabine in Epileptic Patients Under Ongoing Presurgical Assessment
3065A1-212 Completed A multicenter, open-label, long-term, safety tolerability, and efficacy study of retigabine in adult patients with epilepsy (extension of study 205) Study Listed on ClinicalStudyDataRequest.com
3065A1-214 Completed A Randomized, Double-Blind, Parallel-Group, Exploratory Safety and Tolerability Study of 3 Titration Rates of Retigabine (D-23129; GKE-841) Administered as Add-on Therapy in Patients with Refractory Partial Epilepsy Study Listed on ClinicalStudyDataRequest.com
3065A1-216 Completed A Multicenter, Open-Label, Long-Term Extension, Safety and Tolerability Study of Retigabine (GKE-841) in Adult Patients with Epilepsy Study Listed on ClinicalStudyDataRequest.com
347414/008 Completed Study to assess immunogenicity and safety of GSK Biologicals’ investigational vaccination regimen administered concomitantly in separate injections with GSK Biologicals’ DTPa-IPV/Hib vaccine as a primary vaccination course to healthy infants at 2-4-6 months of age and as a booster dose at 12 to 18 months of age Study Listed on ClinicalStudyDataRequest.com
347414/010 Terminated Assess, in young children, the efficacy in preventing acute otitis media (AOM) of GSK Biologicals undecavalent pneumococcal-protein D conjugate vaccine, when administered as a three dose primary vaccination course during the first year of life with a booster dose in the second year of life. Study Listed on ClinicalStudyDataRequest.com
347414/016 Completed A phase II, single-blind, randomised, controlled, multicentre study to evaluate the safety, reactogenicity and immunogenicity of two experimental formulations versus a licensed Haemophilus influenzae type b (Hib) conjugate vaccine (Hiberix™ or HibTiter™) administered as primary vaccination to infants in their thirth, fourth and fifth months of life, with concomitant administration of SmithKline Beecham Biologicals' DTPa-HBV-IPV vaccine Study Listed on ClinicalStudyDataRequest.com
347414/017 Completed A multinational, randomised, controlled, single-blind, phase-II study to evaluate the safety and immunogenicity of two investigational vaccination regimens versus a licensed Haemophilus influenzae type b (Hib) conjugate vaccine (Hiberix) given concomitantly with DTPw-HBV vaccine in a separate injection of DTPw-HBV to infants at 2, 4, and 6 months of age Study Listed on ClinicalStudyDataRequest.com
347414/020 Completed A Phase III, randomized, single blind study to assess the immune response induced by Prevenar™(Wyeth Lederle) when administered to healthy infants with DTPa-HBV-IPV/Hib, compared to an investigational vaccination regimen as a 3-dose primary vaccination course at a monthly interval starting at 8–16 Weeks of age Study Listed on ClinicalStudyDataRequest.com
347414/023 Completed A phase II, single-blind, randomized, controlled study to evaluate the immunogenicity and safety of four different formulations of an investigational vaccination regimen when given intramuscularly as primary vaccination in infants at 3, 4 ½ and 6 months of age. Study Listed on ClinicalStudyDataRequest.com
347414/026 Completed A Phase III, randomized single-blind clinical trial to assess the immune memory induced by an investigational vaccination regimen in comparison with Prevnar and the immune response to a fourth dose of the pneumococcal vaccine and the investigational vaccination regimen, when admininistered to healthy children (12-15 Months) Study Listed on ClinicalStudyDataRequest.com
347414/028 Completed A randomized, controlled, open, phase-II clinical study to evaluate the safety and immunogenicity of an experimental formulation extemporaneously mixed with SmithKline Beecham Biologicals' Haemophilus influenzae type b (Hib) vaccine, administered as a booster dose with DTPa-HBV-IPV to healthy children 12 to 18 months old Study Listed on ClinicalStudyDataRequest.com
347414/029 Completed Multinational, randomised, controlled, open, phase 2 clinical study to evaluate the safety and immunogenicity of GSK Biologicals’ investigational vaccination regimen administered as a booster dose to healthy children, previously vaccinated in infancy with the investigational vaccination regimen in a primary study 347414/017 Study Listed on ClinicalStudyDataRequest.com
347414/035 Completed A phase-III, open, controlled, follow-up clinical trial, with Prevenar as control, to assess the safety of GSK Biologicals’ investigational vaccination regimen administered with DTPa-HBV-IPV/Hib to healthy children, previously vaccinated in infancy with the investigational vaccination regimen in a primary study in the Netherlands Study Listed on ClinicalStudyDataRequest.com
347414/036 Completed A phase-3, open, controlled study to assess the safety and immunogenicity of four different formulations of GSK Biologicals’ investigational vaccination regimen when administered as a booster to healthy infants, 12 to 16 months old, previously vaccinated in infancy in a primary study 347414/023 Study Listed on ClinicalStudyDataRequest.com
371594/006 Completed A phase II, open, randomized study to assess the immune memory induced by a primary vaccination course of an investigational vaccination regimen and the immunogenicity and reactogenicity of a fourth dose of an investigational vaccination regimen, to healthy toddlers primed in study 371594/004. Study Listed on ClinicalStudyDataRequest.com

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.